Logo for Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Investor Relations Material

Latest events

Logo for Catalyst Pharmaceuticals Inc

Q1 2024

Catalyst Pharmaceuticals
Logo for Catalyst Pharmaceuticals

Q1 2024

9 May, 2024
Logo for Catalyst Pharmaceuticals

Q4 2023

29 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Catalyst Pharmaceuticals Inc

Access all reports
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. The company develops oral mid-kine receptor modulators for multiple indications for the treatment of neuromuscular weakness associated with amyotrophic lateral sclerosis. Catalyst Pharmaceuticals has a collaboration agreement with Memorial Sloan Kettering Cancer Center to develop drugs for muscle diseases associated with cancer or its treatment. It also develops a pipeline of compositions covering a range of applications including pain management, sleep disorders, and drug addiction.